Natalizumab

ATC L04AG03 · 10 markets · 26 records

Natalizumab 10 markets · 26 records Forms

AU 7 records · 5 strengths

  • 300 mg/15 mLinjectionTYSABRI also in GB·US·SG
  • 300 mginjectionTYRUKO natalizumab 300 mg/15 mL concentrate for infusion vialTYSABRI natalizumab 300mg/15 mL concentrate for infusion vial also in ES·TW unknown
  • 150 mg/1 mLinjectionTYSABRI also in GB
  • 150 mginjectionTYSABRI natalizumab 150 mg/1 mL injection solution pre-filled syringe also in ES unknown

Records without a stated strength · 1 TYRUKO、TYSABRI

GB 3 records · 2 strengths

  • 300 mg/15 mLinjectionTyruko 300mg/15ml concentrate for solution for infusion vialsTysabri 300mg/15ml concentrate for solution for infusion vials also in AU·US·SG
  • 150 mg/1 mLinjectionTysabri 150mg/1ml solution for injection pre-filled syringes also in AU

ES 3 records · 3 strengths

MX 3 records · 1 strengths

    Records without a stated strength · 1 TYRUKO、TYSABRI、TYSABRI SC

    EU 3 records · 1 strengths

    EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

      Records without a stated strength · 1 Natalizumab Elan Pharma、TYRUKO、TYSABRI

      US 2 records · 1 strengths

      CA 2 records · 1 strengths

      • 20 mg/1 mLliquidTYRUKOTYSABRI

      SG 1 records · 1 strengths

      TW 1 records · 1 strengths

      HK 1 records · 1 strengths

        Records without a stated strength · 1 Tysabri concentrate for solution for infusion 300mg

        Side-by-side table

        The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

        Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.